Newborn screening for lysosomal storage disorders and other neuronopathic conditions

Dietrich Matern, Devin Oglesbee, Silvia Tortorelli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Newborn screening (NBS) is a public health program aimed at identifying treatable conditions in presymptomatic newborns to avoid premature mortality, morbidity, and disabilities. Currently, every newborn in the Unites States is screened for at least 29 conditions where evidence suggests that early detection is possible and beneficial. With new or improved treatment options and development of high-throughput screening tests, additional conditions have been proposed for inclusion into NBS programs. Among those are several conditions with a strong neuronopathic component. Some of these conditions have already been added to a few national and international screening programs, whereas others are undergoing pilot studies to determine the test performance metrics. Here, we review the current state of NBS for 13 lysosomal storage disorders, X-adrenoleukodystrophy, Wilson disease, and Friedreich ataxia.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalDevelopmental Disabilities Research Reviews
Volume17
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Adrenoleukodystrophy
Friedreich Ataxia
Hepatolenticular Degeneration
Premature Mortality
Public Health
Morbidity

Keywords

  • Dried blood spots
  • Immuno-quantification
  • Lysosomal storage disorder
  • Newborn screening
  • Peroxisomal disorders
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Developmental and Educational Psychology
  • Medicine(all)

Cite this

Newborn screening for lysosomal storage disorders and other neuronopathic conditions. / Matern, Dietrich; Oglesbee, Devin; Tortorelli, Silvia.

In: Developmental Disabilities Research Reviews, Vol. 17, No. 3, 2013, p. 247-253.

Research output: Contribution to journalArticle

@article{5cebc15b6d77431d8ecd03c93eb0c7c7,
title = "Newborn screening for lysosomal storage disorders and other neuronopathic conditions",
abstract = "Newborn screening (NBS) is a public health program aimed at identifying treatable conditions in presymptomatic newborns to avoid premature mortality, morbidity, and disabilities. Currently, every newborn in the Unites States is screened for at least 29 conditions where evidence suggests that early detection is possible and beneficial. With new or improved treatment options and development of high-throughput screening tests, additional conditions have been proposed for inclusion into NBS programs. Among those are several conditions with a strong neuronopathic component. Some of these conditions have already been added to a few national and international screening programs, whereas others are undergoing pilot studies to determine the test performance metrics. Here, we review the current state of NBS for 13 lysosomal storage disorders, X-adrenoleukodystrophy, Wilson disease, and Friedreich ataxia.",
keywords = "Dried blood spots, Immuno-quantification, Lysosomal storage disorder, Newborn screening, Peroxisomal disorders, Tandem mass spectrometry",
author = "Dietrich Matern and Devin Oglesbee and Silvia Tortorelli",
year = "2013",
doi = "10.1002/ddrr.1117",
language = "English (US)",
volume = "17",
pages = "247--253",
journal = "Developmental Disabilities Research Reviews",
issn = "1940-5510",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Newborn screening for lysosomal storage disorders and other neuronopathic conditions

AU - Matern, Dietrich

AU - Oglesbee, Devin

AU - Tortorelli, Silvia

PY - 2013

Y1 - 2013

N2 - Newborn screening (NBS) is a public health program aimed at identifying treatable conditions in presymptomatic newborns to avoid premature mortality, morbidity, and disabilities. Currently, every newborn in the Unites States is screened for at least 29 conditions where evidence suggests that early detection is possible and beneficial. With new or improved treatment options and development of high-throughput screening tests, additional conditions have been proposed for inclusion into NBS programs. Among those are several conditions with a strong neuronopathic component. Some of these conditions have already been added to a few national and international screening programs, whereas others are undergoing pilot studies to determine the test performance metrics. Here, we review the current state of NBS for 13 lysosomal storage disorders, X-adrenoleukodystrophy, Wilson disease, and Friedreich ataxia.

AB - Newborn screening (NBS) is a public health program aimed at identifying treatable conditions in presymptomatic newborns to avoid premature mortality, morbidity, and disabilities. Currently, every newborn in the Unites States is screened for at least 29 conditions where evidence suggests that early detection is possible and beneficial. With new or improved treatment options and development of high-throughput screening tests, additional conditions have been proposed for inclusion into NBS programs. Among those are several conditions with a strong neuronopathic component. Some of these conditions have already been added to a few national and international screening programs, whereas others are undergoing pilot studies to determine the test performance metrics. Here, we review the current state of NBS for 13 lysosomal storage disorders, X-adrenoleukodystrophy, Wilson disease, and Friedreich ataxia.

KW - Dried blood spots

KW - Immuno-quantification

KW - Lysosomal storage disorder

KW - Newborn screening

KW - Peroxisomal disorders

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=84893387309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893387309&partnerID=8YFLogxK

U2 - 10.1002/ddrr.1117

DO - 10.1002/ddrr.1117

M3 - Article

C2 - 23798012

AN - SCOPUS:84893387309

VL - 17

SP - 247

EP - 253

JO - Developmental Disabilities Research Reviews

JF - Developmental Disabilities Research Reviews

SN - 1940-5510

IS - 3

ER -